Announcements Trials
Browse Landscape

Phase

Phase 1/2 12Phase 2 2Phase 1 2Phase 2/3 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Neoplasms 8Melanoma 6Carcinoma, Non-Small-Cell Lung 5Colorectal Neoplasms 4Carcinoma, Hepatocellular 4Stomach Neoplasms 3Neoplasm Metastasis 3Lymphoma 3Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Nasopharyngeal Carcinoma 2Liver Neoplasms 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Renal Cell 2Advanced Solid Tumors 2Advanced Solid Tumor 2Uterine Cervical Neoplasms 1Solid Tumor 1Skin Neoplasms 1Sarcoma 1Primary Condition: Advanced Tumors 1Neuroendocrine Tumors 1Mouth Neoplasms 1Lung Neoplasms 1Locoregionally Advanced Laryngo-hypopharyngeal Squamous Cell Cancer 1Kidney Neoplasms 1High-Risk Resectable NSCLC 1Esophageal Neoplasms 1Chondrosarcoma 1Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 11Injections 10tislelizumab 7Nivolumab 4Irinotecan 4Cetuximab 4cediranib 3Paclitaxel 3PM 01183 3Leucovorin 3Gemcitabine 3Fluorouracil 3Cisplatin 3toripalimab 2spartalizumab 2serabelisib 2olaparib 2glumetinib 2camrelizumab 2apatinib 2adagrasib 2Therapeutics 2Pemetrexed 2Oxaliplatin 2Midazolam 2Drug Therapy 2Docetaxel 2Digoxin 2Cyclophosphamide 2Carboplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Advanced Solid Tumor × toripalimab × Clear all
NCT03874897 2024-04-30

Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.

Peking University

Phase 1 Completed
134 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT04357756 2023-09-13

A Study to Assess YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors

Eucure (Beijing) Biopharma Co., Ltd

Phase 1 Completed
29 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡